K
Kevin D. Cooper
Researcher at University Hospitals of Cleveland
Publications - 375
Citations - 22044
Kevin D. Cooper is an academic researcher from University Hospitals of Cleveland. The author has contributed to research in topics: Psoriasis & Antigen. The author has an hindex of 78, co-authored 371 publications receiving 20568 citations. Previous affiliations of Kevin D. Cooper include Oregon Health & Science University & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies
Lawrence F. Eichenfield,Lawrence F. Eichenfield,Wynnis L. Tom,Wynnis L. Tom,Timothy G. Berger,Alfons Krol,Amy S. Paller,Kathryn Schwarzenberger,James N. Bergman,Sarah L. Chamlin,David E. Cohen,Kevin D. Cooper,Kelly M. Cordoro,Dawn Marie R. Davis,Steven R. Feldman,Jon M. Hanifin,David J. Margolis,Robert A. Silverman,Eric L. Simpson,Hywel C Williams,Craig A. Elmets,Julie Block,Christopher G. Harrod,Wendy Smith Begolka,Robert Sidbury +24 more
TL;DR: Treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed and suggestions on dosing and monitoring are given based on available evidence.
Journal ArticleDOI
Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.
Lawrence F. Eichenfield,Wynnis L. Tom,Sarah L. Chamlin,Steven R. Feldman,Jon M. Hanifin,Eric L. Simpson,Timothy G. Berger,James N. Bergman,David E. Cohen,Kevin D. Cooper,Kelly M. Cordoro,Dawn Marie R. Davis,Alfons Krol,David J. Margolis,Amy S. Paller,Kathryn Schwarzenberger,Robert A. Silverman,Hywel C Williams,Craig A. Elmets,Julie Block,Christopher G. Harrod,Wendy Smith Begolka,Robert Sidbury +22 more
TL;DR: This guideline addresses important clinical questions that arise in the management and care of AD, providing updated and expanded recommendations based on the available evidence.
Journal ArticleDOI
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.
Lawrence S. Chan,A. Razzaque Ahmed,Grant J. Anhalt,Wolfgang Bernauer,Kevin D. Cooper,Mark J Elder,Jo-David Fine,C. Stephen Foster,Reza F. Ghohestani,Takashi Hashimoto,Thanh Hoang-Xuan,Gudula Kirtschig,Neil J. Korman,Susan Lightman,Francina Lozada-Nur,M. Peter Marinkovich,M. Peter Marinkovich,Bartly J. Mondino,Catherine Prost-Squarcioni,Roy S. Rogers,Jane Setterfield,Dennis P. West,Fenella Wojnarowska,David T. Woodley,Kim B. Yancey,Detlef Zillikens,John J. Zone +26 more
TL;DR: Specific consensus-based recommendations were made regarding the definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators for mucous membrane pemphigoid.
Journal ArticleDOI
Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents
Robert Sidbury,Dawn Marie R. Davis,David E. Cohen,Kelly M. Cordoro,Timothy G. Berger,James N. Bergman,Sarah L. Chamlin,Kevin D. Cooper,Steven R. Feldman,Jon M. Hanifin,Alfons Krol,David J. Margolis,Amy S. Paller,Kathryn Schwarzenberger,Robert A. Silverman,Eric L. Simpson,Wynnis L. Tom,Wynnis L. Tom,Hywel C Williams,Craig A. Elmets,Julie Block,Christopher G. Harrod,Wendy Smith Begolka,Lawrence F. Eichenfield,Lawrence F. Eichenfield +24 more
TL;DR: The treatment of atopic dermatitis with phototherapy and systemic immunomodulators, antimicrobials, and antihistamines is reviewed in this article, including indications for use and the risk-benefit profile of each treatment option.
Journal ArticleDOI
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
Elise A. Olsen,Madeleine Duvic,Arthur E. Frankel,Youn H. Kim,Ann Martin,Eric C. Vonderheid,Brian V. Jegasothy,Gary S. Wood,Michael S. Gordon,Peter W. Heald,Allan Oseroff,Lauren C. Pinter-Brown,Glen Bowen,Timothy M. Kuzel,David P. Fivenson,Francine M. Foss,Michael Glode,Arturo Molina,Elizabeth Knobler,Stanford J. Stewart,Kevin D. Cooper,Seth R. Stevens,Fiona E. Craig,James M. Reuben,Patricia Bacha,Jean Nichols +25 more
TL;DR: Denileukin diftitox has been shown to be a useful and important agent in the treatment of patients whose CTCL is persistent or recurrent despite other therapeutic interventions.